Role of T lymphocytes in tumor response to radiotherapy, Frontiers in Oncology, vol.2, p.95, 2012. ,
DOI : 10.3389/fonc.2012.00095
Activation of local and systemic anti-tumor immune responses by ablation of solid tumors with intratumoral electrochemical or alpha radiation treatments, Cancer Immunology, Immunotherapy, vol.32, issue.Supl. 1, pp.1-9, 2014. ,
DOI : 10.1007/s00262-013-1462-2
Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors, Cancer Immunology, Immunotherapy, vol.63, issue.2, pp.191-200, 2015. ,
DOI : 10.1007/s00262-014-1626-8
Antitumor Immunity Induced after ?? Irradiation, Neoplasia, vol.16, issue.4, pp.319-347, 2014. ,
DOI : 10.1016/j.neo.2014.04.002
URL : http://doi.org/10.1016/j.neo.2014.04.002
Calreticulin exposure dictates the immunogenicity of cancer cell death, Nature Medicine, vol.279, issue.1, pp.54-61, 2007. ,
DOI : 10.1038/nm1523
URL : https://hal.archives-ouvertes.fr/inserm-00451702
Immunogenic Cell Death in Cancer Therapy, Annual Review of Immunology, vol.31, issue.1, pp.51-72, 2013. ,
DOI : 10.1146/annurev-immunol-032712-100008
External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing, Cancer Research, vol.64, issue.12, pp.4328-4365, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0073
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, The Journal of Experimental Medicine, vol.123, issue.5, pp.1259-71, 2006. ,
DOI : 10.1126/science.274.5284.94
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212727
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes, Cancer Research, vol.64, issue.21, pp.7985-94, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1525
The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing, Clinical Cancer Research, vol.14, issue.13, pp.4241-4250, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0335
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects, Cancer Immunology, Immunotherapy, vol.62, issue.21, pp.1173-83, 2008. ,
DOI : 10.1007/s00262-008-0449-x
Combination of local irradiation with systemic application of anaerobic corynebacteria in therapy of a murine fibrosarcoma, Cancer Res, vol.35, pp.1274-1281, 1975. ,
Combining radiotherapy and immunotherapy: A revived partnership, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.3, pp.655-66, 2005. ,
DOI : 10.1016/j.ijrobp.2005.06.032
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1489884
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift, JNCI Journal of the National Cancer Institute, vol.105, issue.4, pp.256-65, 2013. ,
DOI : 10.1093/jnci/djs629
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576324
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.1597-604, 2013. ,
DOI : 10.2967/jnumed.112.111997
Combining ??-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction, PLOS ONE, vol.62, issue.Suppl 1, p.130249, 2015. ,
DOI : 10.1371/journal.pone.0130249.s001
Immunoth??rapie des cancers par oligonucl??otides immunostimulants, m??decine/sciences, vol.21, issue.1, pp.73-80, 2005. ,
DOI : 10.1051/medsci/200521173
URL : http://www.erudit.org/revue/ms/2005/v21/n1/009994ar.pdf
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of ??-Particle Emitters for Targeted Radionuclide Therapy, Journal of Nuclear Medicine, vol.51, issue.2, pp.311-339, 2010. ,
DOI : 10.2967/jnumed.108.058651
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013. ,
DOI : 10.1056/NEJMoa1213755
Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2074, 2009. ,
DOI : 10.2967/jnumed.109.066993
URL : https://hal.archives-ouvertes.fr/inserm-00442929
Radiobiologic principles in radionuclide therapy, J Nucl Med, vol.46, issue.1, pp.4-12, 2005. ,
Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer, Current Radiopharmaceuticals, vol.6, issue.2, pp.57-71, 2013. ,
DOI : 10.2174/1874471011306020001
The promise of targeted {alpha}-particle therapy, J Nucl Med, vol.46, issue.1, pp.199-204, 2005. ,
Targeted alpha-therapy: past, present, future ?, Dalton Trans, vol.43, pp.4918-4946, 2007. ,
Bismuth-213 and Actinium-225 ??? Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes, Current Radiopharmaceuticals, vol.5, issue.3, pp.221-228, 2012. ,
DOI : 10.2174/1874471011205030221
Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics, Current Topics in Medicinal Chemistry, vol.12, issue.23, pp.2642-54, 2012. ,
DOI : 10.2174/1568026611212230002
Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-754, 2011. ,
DOI : 10.1038/nrclinonc.2011.160
Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, pp.1233-1242, 2002. ,
DOI : 10.14694/EdBook_AM.2014.34.e126
Molecular Pathways: Targeted ??-Particle Radiation Therapy, Clinical Cancer Research, vol.19, issue.3, pp.530-537, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-0298
Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008. ,
DOI : 10.2967/jnumed.107.046938
Sequential Cytarabine and ??-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia, Clinical Cancer Research, vol.16, issue.21, pp.5303-5314, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-0382
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma, Cancer Biology & Therapy, vol.6, issue.6, pp.846-52, 2007. ,
DOI : 10.4161/cbt.6.6.4089
Analysis of patient survival in a Phase I trial of systemic targeted ??-therapy for metastatic melanoma, Immunotherapy, vol.3, issue.9, pp.1041-50, 2011. ,
DOI : 10.2217/imt.11.97
Intraperitoneal ??-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-60, 2009. ,
DOI : 10.2967/jnumed.109.062604
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial, European Journal of Nuclear Medicine and Molecular Imaging, vol.19, issue.4, pp.1335-1379, 2010. ,
DOI : 10.1007/s00259-010-1385-5
Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P, Clinical Cancer Research, vol.12, issue.12, pp.3843-50, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2820
Timeline: Radiation oncology: a century of achievements, Nature Reviews Cancer, vol.4, issue.9, pp.737-784, 2004. ,
DOI : 10.1016/0006-2952(86)90566-6
Trial Watch, OncoImmunology, vol.31, issue.9, p.25595, 2013. ,
DOI : 10.1158/0008-5472.CAN-11-3912
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, pp.862-70, 2004. ,
DOI : 10.1016/j.ijrobp.2003.09.012
Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1??, Clinical Cancer Research, vol.14, issue.4, pp.1159-66, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-4485